Compositions comprising bacterial strains

• US 9,974,815 B2
• Filed: 11/03/2017
• Issued: 05/22/2018
• Est. Priority Date: 11/20/2015
• Status: Active Grant

• Current Assignee: CJ Bioscience Incorporated
• Original Assignee: 4D Pharma Research Limited (4D Pharma PLC)
• Inventors: Mulder, Imke Elisabeth, Holt, Amy Beth, Panzica, Domenico, McClusky, Seanin Marie
• Primary Examiner(s): Baskar, Padmavathi
• Application Number:
  US15/803,723
• Publication Number:
  US 20180055892A1
• Time in Patent Office: 200 Days
• CPC Class Codes: A23C 9/1585 Antibiotics; Bacteriocins; Fungicides from microorganisms
• CPC Class Codes: A23L 33/135 Bacteria or derivatives thereof, e.g. probiotics
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A61K 2035/11 Medicinal preparations comprising living procariotic cells
• CPC Class Codes: A61K 2039/585 wherein the target is cancer
• CPC Class Codes: A61K 31/739 Lipopolysaccharides
• CPC Class Codes: A61K 35/74 Bacteria therapeutic use of a bacterial protein A61K38/00
• CPC Class Codes: A61K 35/744 Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• CPC Class Codes: A61K 39/09 Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/19 lyophilised , i.e. freeze-dried, solutions or dispersions lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C12N 1/20 Bacteria; Culture media therefor
• CPC Class Codes: C12N 1/205 Bacterial isolates
• CPC Class Codes: C12R 2001/46 Streptococcus ; Enterococcus; Lactococcus

Abstract

The invention provides compositions comprising bacterial strains for treating and preventing cancer.

Claims

1. A method of treatment of cancer in a subject in need thereof, comprising:

administering to the subject a therapeutically effective amount of a pharmaceutical composition that comprises;

a bacteria strain with a 16s rRNA gene sequence with at least 99.5% sequence identity to the polynucleotide of SEQ ID NO;

2, wherein the sequence identity is determined by the Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12 and a gap extension penalty of 2, and a BLOSUM matrix of 62;

wherein said bacteria strain has a carbohydrate fermentation profile that comprises;

(i) a positive fermentation of at least one of;

L-arabinose and D-xylose; and

(ii) an intermediate fermentation of Methyl-α

D-glycopyranoside;

wherein said bacteria strain is present in an amount sufficient for treatment of cancer in the subject, and wherein the cancer is a solid tumor cancer.

2. The method of claim 1, wherein said carbohydrate profile further comprises a positive fermentation of at least one of:

D-tagatose, D-ribose, potassium gluconate, D-galactose, D-glucose, D-fructose, D-mannose, N-acetylglucosamine, amygdalin, arbutin, salicin, D-cellobiose, D-maltose, sucrose, D-trehalose, and gentiobiose.

3. The method of claim 1, wherein said carbohydrate profile further comprises an intermediate fermentation of at least one of:

D-mannitol, D-lactose, and starch.

4. The method of claim 1, wherein said carbohydrate profile further comprises:

(i) a positive fermentation of at least one of;

D-tagatose, D-ribose, potassium gluconate, D-galactose, D-glucose, D-fructose, D-mannose, N-acetylglucosamine, amygdalin, arbutin, salicin, D-cellobiose, D-maltose, sucrose, D-trehalose, and gentiobiose; and

(ii) an intermediate fermentation of at least one of;

D-mannitol, D-lactose, and starch.

5. The method of claim 4, wherein said carbohydrate profile comprises a positive fermentation of L-arabinose, D-xylose, and gentiobiose.

6. The method of claim 4, wherein said carbohydrate profile comprises a positive fermentation of L-arabinose and D-xylose and an intermediate fermentation of Methyl-α

D-glycopyranoside.

7. The method of claim 1, wherein the bacteria strain is live and viable.

8. The method of claim 1, wherein said bacteria strain comprises the 16s rRNA gene sequence of SEQ ID NO:

2.

9. The method of claim 1, wherein said bacteria strain is of the species Enterococcus gallinarum.

10. The method of claim 1, wherein said bacteria strain is the bacteria strain deposited under accession number NCIMB 42488.